Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: A prospective phase II study

Radiotherapy and Oncology

Volumn 105, Issue 2, 2012, Pages 161-166

  Mantini, Giovanna ^a   Valentini, Vincenzo ^a   Meduri, Bruno ^a   Margaritora, Stefano ^b   Balducci, Mario ^a   Micciché, Francesco ^a   Nardone, Luigia ^a   De Rose, Fiorenza ^a   Cesario, Alfredo ^b   Larici, Anna Rita ^b   Maggi, Fabio ^b   Calcagni, Maria Lucia ^a   Granone, Pierluigi ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b Department of Thoracic Surgery ^*  (Italy)

Author keywords

Chemopotentiator; Low dose hyper radiosensitivity; Lung cancer; Pemetrexed; Radio chemotherapy

Indexed keywords

CISPLATIN; CORTICOSTEROID; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; GEMCITABINE; PEMETREXED;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS INJURY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; LOW DOSE FRACTIONATED RADIOTHERAPY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RECURRENT CANCER; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE;

EID: 84871291457     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.09.006     Document Type: Article

References (47)

1. D.M. Parkin, F.I. Bray, and S.S. Devessa Cancer burden for the year 2000: the global picture Eur J Cancer 37 2001 S4 S66
2. G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
3. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials BMJ 311 1995 899
4. P.J. Souquet, F. Chauvin, and J.P. Boissel Polychemotherapy in advanced non small cell lung cancer: a meta-analysis Lancet 342 1993 19
5. R. Grilli, A.D. Oxman, and J.A. Julian Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 11 1993 1866
6. P. Marino, S. Pampallona, and A. Preatoni Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature Chest 106 1994 861
7. M.H. Cullen, L.J. Billingham, and C.M. Woodroffe Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life J Clin Oncol 17 1999 3188
8. P.A. Ellis, I.E. Smith, and J.R. Hardy Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer Br J Cancer 71 1995 366
9. D. Tummarello, F. Graziano, and P. Isidori Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C Cancer Chemother Pharmacol 35 1995 249
10. L. Jaakkimainen, P. Goodwin, and J. Pater Counting the costs of chemotherapy in a National Cancer Institute randomized trial in non-small cell lung cancer J Clin Oncol 8 1990 1301
11. T.J. Smith, B.E. Hillner, and D.M. Neighbors Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer J Clin Oncol 13 1995 2166
12. P.J. Goodwin, and F.A. Shepherd Economic issues in lung cancer: a review J Clin Oncol 16 1998 3900 3912
13. F.A. Shepherd, J. Dancey, and R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum based chemotherapy J Clin Oncol 18 2000 2095 2103
14. D.G. Pfister, D.H. Johnson, and C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
15. F.V. Fossella, R. DeVore, and R.N. Kerr Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group J Clin Oncol 18 2000 2354 2362
16. E. Esteban, L. Gonzalez de Sande, and Y. Fernandez Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy Ann Oncol 14 2003 1640 1647
17. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
18. K.D. Rollins, and C. Lindley Pemetrexed: a multitargeted antifolate Clin Ther 27 2005 1343 1376
19. M. Partridge, M. Ramos, and A. Sardaro Dose escalation for non-small cell lung cancer: analysis and modelling of published literature Radiother Oncol 99 2011 6 11
20. M. Saunders, S. Dische, and A. Barrett Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee Radiother Oncol 52 1999 137 148
21. M. Baumann, T. Herrmann, and R. Koch Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC) Radiother Oncol 100 2011 76 85
22. D. Palma, O. Visser, and F.J. Lagerwaard Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery Radiother Oncol 101 2011 240 244
23. Samir Sejpal, Ritsuko Komaki, and Anne Tsao Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer Cancer 117 2011 3004 3013
24. J. Zhu, Z.C. Zhang, and B.S. Li Analysis of acute radiation-induced esophagitis in non-small-cell lung cancer patients using the Lyman NTCP model Radiother Oncol 97 2010 449 454
25. Y.T. Oh, O.K. Noh, and H. Jang The features of radiation induced lung fibrosis related with dosimetric parameters Radiother Oncol 102 2012 343 346
26. D. De Ruysscher, D. Severin, and E. Barnes First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-II Radiother Oncol 97 2010 36 39
27. B. Marples, and M.C. Joiner The response of Chinese hamster V79 cells to low radiation doses: evidence of enhanced sensitivity of the whole cell population Radiat Res 133 1993 41 51
28. B. Marples, P. Lambin, and K.A. Skov Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells Int J Radiat Biol 71 1997 721 735
29. M.C. Joiner, B. Marples, and P. Lambin Low-dose hypersensitivity: current status and possible mechanisms Int J Radiat Oncol Biol Phys 49 2001 379 389
30. B. Marples, B.G. Wouters, and S.J. Collis Low-dose hyper- radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells Radiat Res 161 2004 247 255
31. D. Chendil, R. Oakes, and R.A. Alcock Low-dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53 Cancer 89 2000 1893 1900
32. S. Dey, P. Spring, and S.M. Arnold Low dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines Clin Cancer Res 9 2003 1557 1565
33. S.M. Arnold, W.F. Regine, and M. Mansoor Low-dose fractionated radiation as a chemopotentiator of neoadjuvant Paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm Int J Radiat Oncol Biol Phys 58 2004 1411 1417
34. V. Valentini, M. Massaccesi, and M. Balducci Low-dose hyperradiosensitivity is there a place for future investigation in clinical settings? Int J Radiat Oncol Biol Phys 76 2010 535 539
35. P. Bunn, P. Paoletti, and C. Niyikiza Vitamin B12 and folate reduce toxicity of Alimta (Pemetrexed Disodium, LY231514, MTA) a novel antifolate/antimetabolite Proc Am Soc Clin Oncol 20 2001 76a [Abstract]
36. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumour J Nat Cancer Inst 92 2000 205 216
37. S.C. Short, M. Woodcock, and B. Marples The effects of cell cycle phase on low dose hyperradiosensitivity Int J Radiat Biol Phys 79 2003 99 105
38. B. Marples, B.G. Wouters, and M.C. Joiner An association between the radiation-induced arrest of G2 phase cells and low-dose hyper-radiosensitivity: a plausible underlying mechanism? Radiat Res 160 2003 38 45
39. B. Xu, S.T. Kim, and D.S. Lim Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation Mol Cell Biol 22 2002 1049 1059
40. A. Krempler, D. Deckbar, and P.A. Jeggo An imperfect G2M checkpoint contributes to chromosome instability following irradiation of S and G2 phase cells Cell Cycle 6 2007 1682 1686
41. L. Enns, K.T. Bogen, and J. Wizniak Low-dose radiation hypersensitivity is associated with p53-dependent apoptosis Mol Cancer Res 2 2004 557 566
42. M. Krause, J. Prager, and J. Wohlfarth Ultrafractionation does not improve the results of radiotherapy in radioresistant murine DDL1 lymphoma Strahlenther Onkol 181 2005 540 544
43. M. Krause, J. Wohlfarth, and B. Georgi Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo Int J Radiat Biol 81 2005 751 758
44. P.M. Spring, S.M. Arnold, and S. Shajahan Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck Cell Cycle 3 2004 479 485
45. B. Marples, and S.J. Collis Low-dose hyper-radiosensitivity: past, present and future Int J Radiat Oncol Biol Phys 70 2008 1310 1318
46. W.F. Regine, N. Hanna, and M.C. Garofalo Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm Int J Radiat Oncol Biol Phys 68 2007 172 177
47. F. Rödel, L. Keilholz, and M. Herrmann Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy Int J Radiat Biol 83 2007 357 366